Evidence map›Paper›PMID 31409725›Full record

ArticleBioscience reports2019

MicroRNA-302c enhances the chemosensitivity of human glioma cells to temozolomide by suppressing P-gp expression.

YiHan Wu, Yuan Yao, YongLi Yun, MeiLing Wang, RunXiu Zhu

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

YiHan WuDepartment of Neurology, The Inner Mongolia People's Hospital, Huhhot, Inner Mongolia 010017, China mon_wyhan@163.com.ORCID 0000-0002-6329-9287
Yuan YaoDepartment of Neurology, The Inner Mongolia People's Hospital, Huhhot, Inner Mongolia 010017, China.
YongLi YunDepartment of Neurology, The Inner Mongolia People's Hospital, Huhhot, Inner Mongolia 010017, China.
MeiLing WangDepartment of Neurology, The Inner Mongolia People's Hospital, Huhhot, Inner Mongolia 010017, China.
RunXiu ZhuDepartment of Neurology, The Inner Mongolia People's Hospital, Huhhot, Inner Mongolia 010017, China.
Inner Mongolia People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence indicates that microRNAs (miRNAs) participate in the regulation of chemoresistance in a variety of cancers including glioma. However, the molecular mechanism underlying the development of chemoresistance in glioma is not well understood. The aim of the present study was to explore the role of miRNAs in the chemosensitivity of glioma cells and the underlying mechanism. By microarray and qRT-PCR, we observed significant down-regulation of microRNA-302c (miR-302c) in the temozolomide (TMZ)-resistant human glioma tissues/cells. The low expression of miR-302c was closely associated with poor prognosis and chemotherapy resistant in patients. miR-302c up-regulation re-sensitized U251MG-TMZ cells and LN229-TMZ cells to TMZ treatment, as evidenced by inhibition of the cell viability, cell migration, and invasion capacity, and promotion of the apoptosis after TMZ treatment. Furthermore, P-glycoprotein (P-gp) was identified as a functional target of miR-302c and this was validated using a luciferase reporter assay. In addition, P-gp was found to be highly expressed in U251MG-TMZ cells and there was an inverse correlation between P-gp and miR-302c expression levels in clinical glioma specimens. Most importantly, we further confirmed that overexpression of P-gp reversed the enhanced TMZ-sensitivity induced by miR-302c overexpression in U251MG-TMZ and LN229-TMZ cells. Our finding showed that up-regulation of miR-302c enhanced TMZ-sensitivity by targeting P-gp in TMZ-resistant human glioma cells, which suggests that miR-302c would be potential therapeutic targets for chemotherapy-resistant glioma patients.

Indexed as

Antineoplastic Agents, AlkylatingATP Binding Cassette Transporter, Subfamily B, Member 1Brain NeoplasmsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGliomaHumansMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisTemozolomideAntineoplastic Agents, AlkylatingATP Binding Cassette Transporter, Subfamily B, Member 1MicroRNAsMIRN302A microRNA, humanTemozolomideChemoresistanceHuman gliomaMicroRNA-302cP-pgTemozolomide

Identifiers

PMID31409725
PMCPMC6744599
OpenAlexW2968838457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.